• Facets (new session)
• Description
• Metadata
• Settings
  • Rule: ActivityStreamsMapasEquivalentb3sb3sifpdbprdf-labelfacetshttp://dbpedia.org/resource/inference/rules/dbpedia#http://dbpedia.org/resource/inference/rules/opencyc#http://dbpedia.org/resource/inference/rules/umbel#http://dbpedia.org/resource/inference/rules/yago#http://dbpedia.org/schema/property_rules#http://www.ontologyportal.org/inference/rules/SUMO#http://www.ontologyportal.org/inference/rules/WordNet#http://www.w3.org/2002/07/owl#ldpoplwebskos-transurn:det:rdf:labelvirtrdf-labelvirtrdf-urlNone
    
  • Inverse Functional Properties: Disabled (fastest) Apply to subjects only Apply to objects only Apply to both subjects and objects
  • "Same As": Disabled (fastest) Apply to subjects only Apply to objects only Apply to both subjects and objects (recommended) Apply to subjects, objects and predicates (not recommended on big datasets) Apply to predicates only (special use cases only)

About: 5-EAPB     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : yago:WikicatDesignerDrugs, within Data Space : dbpedia.demo.openlinksw.com associated with source document(s)

Type: Thingdul:ChemicalObjectchemical substanceDrugyago:WikicatAmphetaminesyago:Agent114778436yago:Amphetamine102704153yago:CausalAgent100007347yago:DesignerDrug103179489yago:Drug103247620yago:DrugOfAbuse103248958yago:Matter100020827yago:PhysicalEntity100001930yago:PsychoactiveDrug104017137drugyago:Stimulant104320126yago:Substance100020090yago:WikicatDesignerDrugs New Facet based on Instances of this Class

5-EAPB (1-(benzofuran-5-yl)-N-ethylpropan-2-amine) is a potentially entactogenic amphetamine which is structurally related to 5-MAPB and 5-APB. It might be predicted to show similar effects to these drugs in humans, but the pharmacology of 5-EAPB remains unstudied as of 2020. 5-EAPB is similar in structure to compounds such as 5-APB which are claimed to be agonists of the 5-HT2C receptor as well as a triple monoamine reuptake inhibitor, however 5-EAPB is not listed as an example in this patent, and it is not yet established to what extent the activity of 5-EAPB resembles that of 5-APB.